Product image of Icatibant Newbury (Icatibant) supplied by GNH India

Icatibant Newbury

Active Ingredient:
Icatibant
Origin:
EU

Icatibant Newbury (Icatibant)

Icatibant, the active ingredient in Icatibant Newbury, is a bradykinin B2 receptor antagonist presented as a subcutaneous formulation for subcutaneous use. It treats acute attacks of hereditary angioedema in patients with confirmed HAE.
GNH India supplies Icatibant Newbury as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Newbury Pharmaceuticals Ab

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Icatibant is a targeted therapy for bradykinin‑mediated angioedema conditions.

  • Acute hereditary angioedema (HAE) attacks: provides rapid relief of swelling and associated symptoms.
  • Hereditary angioedema type I and II: reduces frequency and severity of episodic attacks.
  • Bradykinin‑mediated angioedema (non‑HAE): helps control swelling when bradykinin is the primary mediator.

How It Works

  • Icatibant selectively blocks the bradykinin B2 receptor on vascular endothelial cells, preventing bradykinin‑induced vasodilation and increased vascular permeability. By antagonizing this receptor, it halts the cascade that leads to fluid extravasation and tissue swelling, thereby mitigating acute angioedema episodes.

Side Effects

Icatibant may cause a range of adverse reactions following subcutaneous administration.

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Redness or erythema: localized skin irritation.
  • Swelling at injection site: transient edema.
  • Nausea: occasional gastrointestinal upset.
  • Headache: mild to moderate intensity.
  • Dizziness: transient light‑headedness.

Serious or Rare Side Effects

  • Hypersensitivity reactions: rash, pruritus, or anaphylaxis.
  • Severe hypotension: marked drop in blood pressure.
  • Angioedema unrelated to HAE: unexpected swelling.
  • Urticaria: hives or wheals.
  • Injection site necrosis: tissue damage at the site.
  • Severe abdominal pain: persistent or worsening abdominal discomfort.

Precautions & Warnings

Before using Icatibant, consider the following safety measures.

  • Pregnancy: consult a healthcare professional; safety data are limited.
  • Breastfeeding: use with caution; potential exposure to the infant is unknown.
  • Renal impairment: dose adjustment may be required; monitor renal function.
  • Concomitant ACE inhibitors or ARBs: increased risk of angioedema; assess benefit‑risk.
  • Known hypersensitivity: avoid if allergic to icatibant or any excipients.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Icatibant can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

  • ACE inhibitors: heightened risk of angioedema; avoid concurrent use.
  • Angiotensin receptor blockers (ARBs): may increase angioedema risk; avoid.
  • Other bradykinin B2 antagonists: additive pharmacologic effect; avoid.
  • C1‑esterase inhibitor concentrates: potential interference with therapeutic effect; avoid.

Moderate Interactions (Monitor Closely)

  • Estrogen‑containing contraceptives: may modify HAE severity; monitor.
  • Diuretics: can affect fluid balance; observe for hypotension.
  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): may exacerbate angioedema; monitor closely.

Frequently Asked Questions

Icatibant Newbury is prescribed to treat acute attacks of hereditary angioedema (HAE). It works by rapidly reducing swelling caused by excess bradykinin, providing relief during HAE episodes.

Icatibant blocks the bradykinin B2 receptor on blood vessels, preventing bradykinin from causing vasodilation and increased permeability. This inhibition stops the fluid leakage that leads to swelling in HAE attacks.

The dose of Icatibant Newbury is determined by the prescribing clinician based on the patient’s condition, weight, and severity of the HAE attack. Only a qualified healthcare professional should set the dosing regimen.

Safety data for icatibant in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using the medication.

To request Icatibant Newbury, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Icatibant is a bradykinin B2 receptor antagonist, whereas other HAE therapies, such as C1‑esterase inhibitor concentrates, replace a deficient protein. Icatibant offers a rapid, subcutaneous option that directly blocks bradykinin, making it useful for patients who prefer self‑administration or have contraindications to protein‑based products.

Icatibant should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. Do not use the medication if it has been exposed to temperatures outside this range.

Icatibant is given by subcutaneous injection, typically into the abdomen or thigh. The injection is performed by the patient or a caregiver following the instructions provided by the prescribing clinician, using a pre‑filled syringe or autoinjector as supplied.

Serious risks include hypersensitivity reactions such as anaphylaxis, severe hypotension, and unexpected angioedema unrelated to HAE. Patients should be monitored for signs of allergic reaction, sudden blood pressure drops, or worsening swelling and seek immediate medical attention if these occur.

Icatibant is contraindicated in individuals with known hypersensitivity to icatibant or any of its excipients. It should also be avoided in patients currently receiving ACE inhibitors, ARBs, or other bradykinin B2 antagonists due to the heightened risk of angioedema.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Icatibant

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT